EIGR Eiger BioPharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EIGR

Price (delayed)

$1.1

Market cap

$48.73M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.21

Enterprise value

$73.97M

Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis.

Highlights
The revenue has increased by 34% year-on-year and by 11% since the previous quarter
The gross profit has grown by 26% year-on-year and by 12% since the previous quarter
The equity has plunged by 64% YoY and by 36% from the previous quarter
The debt has increased by 24% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.eigerbio.com
Peers: NRC NWBO

Key stats

What are the main financial stats of EIGR
Market
Shares outstanding
44.3M
Market cap
$48.73M
Enterprise value
$73.97M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
3.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
Earnings
Revenue
$14.93M
EBIT
-$92.37M
EBITDA
-$91.54M
Free cash flow
-$89.11M
Per share
EPS
-$2.21
Free cash flow per share
-$2.02
Book value per share
$0.8
Revenue per share
$0.34
TBVPS
$2.25
Balance sheet
Total assets
$99.23M
Total liabilities
$63.99M
Debt
$40.43M
Equity
$35.24M
Working capital
$72.91M
Liquidity
Debt to equity
1.15
Current ratio
4.04
Quick ratio
3.3
Net debt/EBITDA
-0.28
Margins
EBITDA margin
-613.2%
Gross margin
87.6%
Net margin
-649.2%
Operating margin
-624.2%
Efficiency
Return on assets
-73.6%
Return on equity
-142.6%
Return on invested capital
-76.1%
Return on capital employed
-122.8%
Return on sales
-618.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EIGR stock price

How has the Eiger BioPharmaceuticals stock price performed over time
Intraday
-1.79%
1 week
-4.35%
1 month
0%
1 year
-83.38%
YTD
-6.78%
QTD
22.64%

Financial performance

How have Eiger BioPharmaceuticals's revenue and profit performed over time
Revenue
$14.93M
Gross profit
$13.08M
Operating income
-$93.18M
Net income
-$96.92M
Gross margin
87.6%
Net margin
-649.2%
The revenue has increased by 34% year-on-year and by 11% since the previous quarter
The gross profit has grown by 26% year-on-year and by 12% since the previous quarter
The operating margin rose by 16% year-on-year and by 9% since the previous quarter
The net margin has increased by 16% YoY and by 10% QoQ

Growth

What is Eiger BioPharmaceuticals's growth rate over time

Valuation

What is Eiger BioPharmaceuticals stock price valuation
P/E
N/A
P/B
1.38
P/S
3.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.95
Eiger BioPharmaceuticals's EPS has increased by 12% YoY and by 4.7% QoQ
The equity has plunged by 64% YoY and by 36% from the previous quarter
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 3.3 and 37% less than its last 4 quarters average of 2.2
EIGR's price to sales (P/S) is 74% lower than its last 4 quarters average of 12.6
The revenue has increased by 34% year-on-year and by 11% since the previous quarter

Efficiency

How efficient is Eiger BioPharmaceuticals business performance
Eiger BioPharmaceuticals's ROE has plunged by 53% YoY and by 23% from the previous quarter
EIGR's return on assets is down by 24% year-on-year and by 11% since the previous quarter
Eiger BioPharmaceuticals's return on sales has increased by 16% YoY and by 10% QoQ
The company's return on invested capital rose by 2.9% YoY

Dividends

What is EIGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EIGR.

Financial health

How did Eiger BioPharmaceuticals financials performed over time
EIGR's total assets is 55% higher than its total liabilities
EIGR's total assets is down by 35% YoY and by 17% QoQ
The quick ratio has declined by 18% since the previous quarter and by 11% year-on-year
The debt is 15% higher than the equity
The equity has plunged by 64% YoY and by 36% from the previous quarter
The company's debt to equity has surged by 58% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.